Abstract
Multidrug resistance (MDR) is associated with the expression of P-glycoprotein (P-gp), an ATP-dependent transporter which expels anti-cancer drugs from cells. In the present study, MDR1 P-gp was immunodetected by Western blot analysis in 60 human brain tumors, including meningiomas, schwannomas, low-grade gliomas (astrocytomas, pilocytic astrocytomas) and high-grade gliomas (anaplastic astrocytomas, glioblastomas and anaplastic oligodendrogliomas). Most samples from primary tumors expressed P-gp at the same levels as normal brain tissue except for schwannomas, in which levels were reduced by 65%, and meningiomas, in which levels were more than 10-fold higher in 7 of 10 samples. P-gp levels were 70% and 95% lower in brain metastases from melanomas and lung adenocarcinomas, respectively, than in normal brain tissue. These results indicate that the majority of primary brain tumors express MDR1 P-gp and that its high expression levels in meningiomas may be a marker for this type of brain tumor. © 2001 Wiley-Liss, Inc.
Author supplied keywords
Cite
CITATION STYLE
Demeule, M., Shedid, D., Beaulieu, É., Del Maestro, R. F., Moghrabi, A., Ghosn, P. B., … Béliveau, R. (2001). Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors: P-GP in Brain Tumors. International Journal of Cancer, 93(1), 62–66. https://doi.org/10.1002/ijc.1306
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.